Example A — Three tumors, largest 3 cm
Clinical: TURBT of three papillary tumors (0.8 cm, 1.5 cm, 3.0 cm), all completely resected.
Code(s): 52235 x 1 (largest tumor 2.0–5.0 cm; one code per session).
Dx: C67.- by site if malignancy is known (appearance or recurrence); D49.4 if not yet confirmed; D41.4 only when pathology returns uncertain behavior.

Example B — Small recurrences fulgurated in the office
Clinical: Two 3-mm recurrent papillary lesions fulgurated at surveillance cystoscopy.
Code(s): 52224.
Dx: C67.- (recurrent active disease).

Example C — TURBT with same-day mitomycin
Clinical: 1.5 cm tumor resected; single-dose mitomycin instilled before discharge.
Code(s): 52234 + J9280 for the drug; 51720 is not separately reported — NCCI bundles it into the same-session resection.
Dx: C67.-.

• Size: measured size of each tumor, largest explicitly identified, in cm — measured or estimated before resection (specimens shrink; your size governs)
• Number and location: every lesion mapped — dome, trigone, lateral/anterior/posterior wall, bladder neck
• Action per lesion: resected, fulgurated, or biopsied — the verbs select the code family
• Completeness: complete vs partial resection, and the plan if partial
• Instillation: drug, dose, timing when same-day chemo is given

• Incorrect diagnosis coding: payers increasingly reject C67.9 (bladder cancer, site unspecified) as non-specific even with full digits — document the location and code the site (C67.0–C67.8); use D49.4 pre-pathology; drop the hematuria code once the neoplasm diagnosis is established.
• Multiple TURBT units: one code per session — size drives selection, not count.
• Undocumented size: "large tumor" without a measurement cannot defend 52240 on review.
• Unbundled biopsy: same-lesion biopsy is included in the resection.
• Dx games on hematuria: use the active symptom code on the workup claim, then the confirmed neoplasm code going forward.

How to choose: one code per session, by the size of the largest tumor and the action performed. The codes are mutually exclusive, and each carries an MUE of 1 as a date-of-service edit — not appealable — so one unit of one code, even for multiple tumors or areas.

• 52234 – Cystourethroscopy with fulguration and/or resection; SMALL bladder tumor(s) (0.5–2.0 cm)
• 52235 – MEDIUM bladder tumor(s) (2.0–5.0 cm)
• 52240 – LARGE bladder tumor(s) (>5.0 cm)

• 52224 – fulguration (including cryo/laser) or treatment of MINOR (≤0.5 cm) lesion(s), with or without biopsy
• 52214 – fulguration of trigone/bladder neck/prostatic fossa/urethra bleeding or minor lesions
• 52204 – cystourethroscopy with biopsy(s)

• 51720 – bladder instillation of anticarcinogenic agent — NCCI bundles it into 52224, 52234, 52235, and 52240 same-session; it is separately billable with 52204 and 52214 without a modifier. The drug (e.g., J9280 mitomycin) is reportable with the resection codes even when the instillation is not — prior-authorize it. A separate-encounter instillation supports -XE/-59.
• 52250 – cystourethroscopy with insertion of radioactive substance (when performed)

• C67.0–C67.6 – Malignant neoplasm of bladder, site-specific (trigone, dome, lateral wall, anterior wall, posterior wall, bladder neck, ureteric orifice)
• C67.8 – Malignant neoplasm of overlapping sites of bladder (tumor spanning more than one wall/location)
• C67.9 – Malignant neoplasm of bladder, unspecified — payers increasingly reject this as non-specific; document the site and use the codes above
• D49.4 – Neoplasm of unspecified behavior of bladder — the workhorse pre-pathology code for a tumor seen but not yet biopsied; no site-specific variants, but still document location for the later C67 selection
• D41.4 – Neoplasm of uncertain behavior of bladder — reserved for pathology that has returned inconclusive as to malignancy
• D09.0 – Carcinoma in situ of bladder
• R31.0 – Gross hematuria (workup encounters)
• Z85.51 – Personal history of bladder cancer (post-eradication surveillance)

Tip: site-specific C67 codes beat C67.9 on medical-necessity edits — the op note maps every lesion anyway; use it. And practice diagnostic hygiene: once the bladder neoplasm code is on the claim, drop the hematuria code — the bleeding is part of the disease state.

• Measurements: tumor sizes in cm, measured or estimated before resection, largest identified — the tumor's size, not the resection defect's
• Lesion map: number, sites, action per lesion
• Depth/completeness: muscle in the specimen noted; complete vs staged resection
• Same-day chemo: drug, dose, and timing when instilled

• TURBT family, 52204, 52214, 52224: 0-day globals — follow-up visits and surveillance cystos bill separately.
• -25 when a separately identifiable E/M accompanies the procedure — the documentation must support a separate and significant service, and with bladder tumor patients a legitimately separate same-day E/M is the exception, not the rule: the cancer journey is usually already diagnosed and related. Use -25 sparingly and defensibly — payer scrutiny is rising, and the CY2027 PFS proposed rule targets modifier-25 same-day E/Ms for a payment reduction.
• -58/-78 conventions do not apply the way they do after 90-day-global surgery — each session stands alone.

• 51720 is bundled into 52224–52240 same-session; payers view the catheter and instillation during surgery as part of the procedure. Bill the drug; skip the instillation code.
• An instillation performed at a genuinely separate encounter the same day is separately reportable with -XE (or -59) — PRS has had success when the record shows a totally separate effort and encounter.

• Facility charge capture: the same TURBT/fulguration/biopsy codes, selected from the op note; one TURBT code per session on the facility claim too.
• Same-day instillation: 51720 is bundled into the resection codes (52224–52240) on same-session claims — capture the drug; 51720 remains billable with 52204/52214. Mitomycin and gemcitabine carry different packaging status under OPPS: J9280 mitomycin is separately payable (status indicator K), while J9201 gemcitabine is packaged (status indicator N).
• Supplies: resectoscope loops and disposables per facility charge policy.

• C67.- by site / D49.4 (seen, not yet biopsied) / D41.4 (pathology uncertain) / D09.0 per pathology status — avoid C67.9 when the site is documented
• R31.0 on hematuria-workup encounters

Facility tip: align dx selection and sequencing with the professional claim; update both once pathology returns.

• Op note detail: sizes, sites, and actions in the facility record
• MAR: same-day chemotherapy drug, dose, and timing
• Record alignment: op note, nursing record, pathology requisition, supply log, and charge capture must tell the same story

• Site-of-service variance: TURBT runs ASC/HOPD; minor fulguration and surveillance work is shifting to the office — track the payment differentials.
• Packaging rules vary: drugs and supplies package differently in ASC vs HOPD.
• Audit posture: size-based code selection is chart-auditable — the measurement must be in the op note, not inferred.